FDA Approves Breakthrough Drug Rasonque for Advanced Pancreatic Cancer

FDA Approves Rasonque for Metastatic Pancreatic Cancer

Targeting the Once-Undruggable RAS Mutations

Sold under the brand name Rasonque, the medication targets multiple mutations of the RAS gene family. These mutations drive rapid tumor growth in more than 90 percent of pancreatic cancer cases.

For decades, researchers considered this specific protein structure “undruggable.” Its surface made it exceptionally difficult for pharmaceutical compounds to attach. Revolution Medicines utilizes a molecular glue technology to bind with these stubborn KRAS subtypes, opening doors for therapies that were previously out of reach.

Clinical Trial Data Shows Doubled Survival

Clinical trial data demonstrates that the daily pill significantly extends patient survival compared to standard chemotherapy regimens. In a company-funded study tracking 500 patients whose metastatic cancer stopped responding to earlier treatments, participants taking daraxonrasib achieved a median overall survival of 13.2 months.

Patients in the control arm receiving standard chemotherapy recorded a median survival of roughly 6.7 months.

Fast-Tracked Review and High Costs

The FDA reviewed the application under the Commissioner’s National Priority Voucher Program, accelerating the timeline down to 10 months from the standard 12 months. The agency also granted the drug a “Breakthrough Therapy” designation in June 2025.

Acting FDA Commissioner Kyle Diamantas stated that delivering meaningful treatments quickly is a fundamental duty of the agency, while Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence, called the results unprecedented for an area of high unmet need.

Financial and accessibility details accompanied the approval announcement. Revolution Medicines reported that a one-month supply of Rasonque will cost approximately $39,800.

Prior to the official regulatory clearance, public interest surged after former Sen. Ben Sasse, R-Neb., discussed his experience taking the drug on CBS program “60 Minutes,” reporting reduced pain levels. That public visibility prompted the FDA to permit expanded access criteria for qualifying patients.

An Exceptional Milestone, Not a Cure

Medical professionals emphasize that while the medication represents a major milestone, it is not a cure. Dr. Andrew Coveler of the Fred Hutch Cancer Center told reporters that the medicine marks a significant improvement rather than a final solution. Similarly, Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at the Dana-Farber Cancer Institute, described the approval as an exceptional moment and a foundation for future advances against the disease.

The American Cancer Society estimates that approximately 67,000 new cases of pancreatic cancer will be diagnosed in the United States, with more than 52,000 deaths expected. Because the disease spreads aggressively before detection, its five-year overall survival rate sits at 13 percent.

Oncologists hope the success of daraxonrasib will spur further clinical trials across other difficult tumor types, including lung cancer, where researchers are already testing similar targeted approaches.